ImmunityBio’s Revenue Surge Meets a $632 Million Accounting Quirk

ImmunityBio reports 168% revenue growth driven by Anktiva, but GAAP net loss hits $632.8M due to fair-value adjustments; adjusted loss narrows, and clinical milestones loom.

ImmunityBio is sprinting toward commercialization, but its first-quarter 2026 scorecard offers a study in contrasts. The immunotherapy developer posted a 168% year-over-year revenue jump, yet its GAAP net loss ballooned to $632.8 million from $129.6 million in the same period last year. The headline figure looks punishing—until you peel back the layers.

The culprit behind that eye-watering loss isn’t operational bleeding but accounting mechanics. Non-cash charges tied to fair-value adjustments on warrants, derivative liabilities, and a related-party convertible note—all triggered by the stock’s rally during the quarter—inflated the bottom line. Strip those out, and the adjusted net loss came in at $86.2 million, barely budging from the $82.7 million recorded a year earlier.

Anktiva Drives Commercial Momentum

Net product revenue hit roughly $44.2 million, a 15% sequential gain from the prior quarter. The growth engine remains Anktiva, the company’s lead immunotherapy now approved in five regulatory jurisdictions covering about 34 countries. Macau became the first Asian market to sign off, while commercial availability recently expanded into the MENA region.

The cash position tells a similar story of strengthening. As of March 31, ImmunityBio held $380.9 million in cash and marketable securities, up from $242.8 million at the end of 2025. That war chest is being deployed aggressively: research and development spending climbed to $68.0 million from $48.2 million in the first quarter of 2025, driven by clinical trial costs and manufacturing scale-up.

Clinical Pipeline Nears Key Inflection

Beyond the balance sheet, the clinical calendar is filling up. The pivotal QUILT-2.005 study, testing Anktiva in combination with BCG in BCG-naïve patients with non-muscle invasive bladder cancer, has completed enrollment. An independent data monitoring committee confirmed no additional recruitment is needed, clearing the path for a supplemental approval filing in the second half of 2026.

Adding to the momentum, the National Comprehensive Cancer Network updated its oncology guidelines to recommend Anktiva plus BCG for patients with papillary BCG-resistant NMIBC, expanding on the existing recommendation for carcinoma in situ.

AUA Data Drop Offers Fresh Catalyst

Investors will get another look at Anktiva’s competitive positioning at the upcoming American Urological Association annual meeting. Management plans to present head-to-head comparative data pitting Anktiva in combination with BCG against established rival therapies. The company will also unveil findings from its recombinant BCG program, which aims to address global supply shortages of traditional bladder cancer treatments.

Analysts view the stock’s recent trading range between $7.50 and $8.30 as a holding pattern. The final quarterly numbers and the AUA data set form the next hard test. If the comparative results hold up, Anktiva could solidify its standing as a preferred combination therapy in urologic oncology—and give the market reason to look past the non-cash noise in the income statement.